Grand Pharmaceutical Group Limited
0512.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.6B
Close$
$6.69
41.4% upside
Current Fair Value
41.4% upsideUndervalued by 41.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.60 Billion |
|---|---|
| Enterprise Value | $21.20 Billion |
| Dividend Yield | $0.17 (3.57%) |
| Earnings per Share | $0.35 |
| Beta | 0.7 |
| Outstanding Shares | 3,501,810,000 |
Return
| Return on Equity | 18.61% |
|---|---|
| Return on Assets | 11.43% |
| Return on Invested Capital | 18.04% |
Valuation & Multiples
| P/E Ratio | 14.79 |
|---|---|
| PEG | -160.86 |
| Price to Sales | 0.79 |
| Price to Book Ratio | 1.18 |
| Enterprise Value to Revenue | 0.87 |
| Enterprise Value to EBIT | 5.34 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 17, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Grand Pharmaceutical Group Limited
12,614 employees
CEO: Chao Zhou Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutic...